The antidepressant vortioxetine is a 5-HT 3 -R, 5-HT 7 -R and 5-HT 1D -R antagonist, 5-HT 1B -R partial agonist, 5-HT 1A -R agonist, and serotonin (5-HT) transporter (SERT) inhibitor. Vortioxetine occupies all targets at high therapeutic doses and only SERT and 5-HT 3 -R at low doses. Vortioxetine increases extracellular monoamine concentrations in rat forebrain more than selective serotonin reuptake inhibitors (SSRI) and shows pro-cognitive activity in preclinical models. Given its high affinity for 5-HT 3 -R (Ki ¼ 3.7 nM), selectively expressed in GABA interneurons, we hypothesized that vortioxetine may disinhibit glutamatergic and monoaminergic neurotransmission following 5-HT 3 -R blockade.
Introduction
Vortioxetine (Lu AA21004) is an antidepressant with a clinical efficacy similar to venlafaxine (Alvarez et al., 2012) . Vortioxetine inhibits the serotonin (5-HT) transporter (SERT) and shows high in vitro affinity for several 5-HT receptors (5-HT-R), including 5-HT 3 , 5-HT 1A , 5-HT 1B and 5-HT 7 (Mork et al., 2012; Sanchez et al., 2015) . Vortioxetine has pro-cognitive effects in rodent models (B etry et al., 2015; Sanchez et al., 2015; Wallace et al., 2014) and its administration to rodents increases very markedly the extracellular concentration of monoamines in forebrain to an extent greater than that produced by selective serotonin reuptake inhibitors (SSRI). This difference is most likely due to the multimodal pharmacological profile of vortioxetine, which may prevent local (e.g., mediated by 5-HT 1A and 5-HT 1B autoreceptors) and distal self-inhibitory mechanisms on monoamine cell groups.
Self-inhibitory mechanisms triggered by 5-HT autoreceptors in response to antidepressant drug administration were identified two decades ago (Artigas et al., 1996 Piñeyro and Blier, 1999) . In addition to these local mechanisms, distal loops may also modulate serotonergic activity. Among them, long distance afferents from the medial prefrontal cortex (mPFC) tightly control serotonergic activity Hajos et al., 1998; MartinRuiz et al., 2001 ) and play a major role in the response to behavioural challenges (Warden et al., 2012) . The PFC also projects to the brainstem catecholamine nuclei (Gabbott et al., 2005) and thus, changes in PFC activity may also evoke downstream changes in the activity of the ascending dopaminergic and noradrenergic systems. The PFC contains a high density of neurons expressing 5-HT 1A -R , whose physiological activation inhibits pyramidal neuron activity (Amarg os-Bosch et al., 2004; Puig et al., 2005) . Therefore, 5-HT 1A -R activation by vortioxetine might modulate pyramidal output to brainstem catecholamine nuclei and increase forebrain catecholamine release, as reported for 5-HT 1A -R agonists (Díaz-Mataix et al., 2006; Hajos-Korcsok and Sharp, 1996) .
In addition, given the high affinity (3.7 nM) of vortioxetine for 5-HT 3 -R (Mork et al., 2012) , they may also participate in the distinctive actions of vortioxetine, compared with SSRIs. 5-HT 3 -R are present in forebrain GABAergic interneurons that control pyramidal neuron activity in hippocampus and PFC (Morales and Bloom, 1997; Puig et al., 2004) . 5-HT 3 -R are ion channels and their physiological activation by endogenous 5-HT markedly excites mPFC GABA interneurons .
Using single unit recordings in anesthetized rats, we examined the involvement of 5-HT 3 -R in the mechanism of action of vortioxetine, under the working hypothesis that 5-HT 3 receptor blockade in GABA interneurons may disinhibit pyramidal neuron activity in mPFC. Likewise, using in vivo microdialysis in freelymoving rats, we examined the role of 5-HT 3 -R blockade as a potential negative feed-back mechanism involved in the control of 5-HT release during SERT blockade by antidepressant drugs.
Material and methods

Animals and stereotaxic surgery
Male albino Wistar rats (Iffa Credo, Lyon, France) weighing 250e340 g were used. Animal care followed European Union regulations (directive 2010/63 of September 22, 2010) and was approved by the Institutional Animal Care and Use Committee.
Drugs and treatments
Vortioxetine (VOR) hydrobromide and escitalopram oxalate (ESCI) were provided by H. Lundbeck A/S (Copenhagen-Valby, Denmark). Ondansetron hydrochloride dihydrate (OND, 5-HT 3 -R antagonist), SR57227A (SR, 5-HT 3 -R agonist), baclofen (BAC, GABA B -R agonist) and muscimol (MUS, GABA A -R agonist) were purchased from Sigma-Aldrich (Buchs, Switzerland). Concentrated stock solutions were prepared in hydroxyl-propyl-ß-cyclodextrin 30% (VOR), saline (for systemic administrations) or artificial cerebrospinal fluid (aCSF, for local perfusions) and aliquots were stored at À20 C. Working solutions were prepared daily by dilution. In electrophysiological experiments, drugs were administered intravenously (i.v.) through the femoral vein. In microdialysis experiments, drugs were administered subcutaneously (s.c.) or locally, by reverse microdialysis. The doses used were taken from the literature (Abell an et al., 2000a (Abell an et al., , 2000b B etry et al., 2013; Mork et al., 2012; Zhang et al., 2011) or from pilot experiments.
Electrophysiological recordings
Electrophysiological recordings were performed as previously described (Kargieman et al., 2007; Puig et al., 2005) typically between 9 a.m. and 3 p.m. Rats were anesthetized with chloral hydrate (induction: 400 mg/kg i.p.]; maintenance: 50e70 mg/kg/h i.p. using a perfusion pump) to analyze the responses of layer V mPFC pyramidal neurons (AP from þ3.4 to þ3.2; ML from À0.5 to À0.9; DV from À1.5 to À4; mm) (Paxinos and Watson, 2005) (Fuller and Schlag, 1976) . Both stimulation sites identify the same population of midbrain-projecting PFC neurons (V azquez-Borsetti et al., 2011) . DR and VTA were stimulated at 0.5e2.0 mA, 0.2 ms square pulses, 0.9 Hz as previously reported (Puig et al., 2005) . Of the 73 recorded neurons, 62 (85%) projected to DR, 6 (8%) projected to VTA and 5 (7%) projected to both areas. Neurons not responding to antidromic activation or without spontaneous firing activity were discarded.
The recording electrodes were filled with saline 2M (impedances 6e12 MU). Single unit recordings were amplified with a Neurodata IR283 (Cygnus Technology Inc., Delaware Water Gap, PA), post-amplified and filtered with a Cibertec amplifier (Cibertec, Madrid, Spain) and computed on-line using a DAT 1401plus interface system Spike2 software (Cambridge Electronic Design, Cambridge, UK).
Pontamine Sky Blue was added for the identification of the recording site. After obtaining a stable baseline recording for 5 min, saline or SR was injected as pre-treatment. After 3e5 min, drugs were administered i.v. Cumulative doses were injected every 3 min. Typically, actual recording time was 23e40 min.
In vivo microdialysis
Microdialysis procedures were conducted as previously described (Amarg os-Bosch et al., 2004) . Briefly, anesthetized rats (sodium pentobarbital, 60 mg/kg i.p.) were stereotaxically implanted with concentric microdialysis probes equipped with a 4-mm Cuprophan membrane in the mPFC (AP þ3.2, ML À0.8, DV e6.0 mm from skull) or ventral hippocampus (vHPC) (AP -5.3, ML -4.8, DV -8.8 mm from skull). Microdialysis experiments were carried out in freely-moving rats 20e24 h after surgery at the same time interval as the electrophysiological experiments. Probes were continuously perfused with aCSF pumped at 1.5 mL/min. Dialysate samples of 30 mL were collected every 20 min.
After an initial 60 min stabilization period, four baseline samples were collected before systemic or local pharmacological treatments. In a first set of experiments, ESC and OND were administrated both s.c. to study their effect on extracellular 5-HT in mPFC and vHPC. In experiments examining the role of hippocampal 5-HT 3 -R in augmenting the effect of SERT inhibition on extracellular 5-HT, ESC or VOR was administered s.c. Once a stable effect was achieved, the perfusion fluid was replaced by one containing OND and/or BAC (or MUS). Dialysate 5-HT concentrations were analyzed by HPLC-amperometric detection (Hewlett Packard-1049, Palo Alto, CA, USA) at þ0.60 V, with detection limit of 2 fmol/sample.
Histology
After experimental procedures were completed, animals were euthanized by an anaesthetic overdose. The brains were removed, frozen on dry ice and kept at À80 C before being cut into coronal sections (50 mm) with a cryostat. Brain sections were stained to verify the recording and stimulation sites with neutral red or the correct placement of the probes with fast-green. e25th min after a single dose drug injection). Neurons were considered to be excited or inhibited when drugs induced a ±30% change of the discharge rate at least in two consecutive doses or time periods (Kargieman et al., 2007) .
Microdialysis data are given as percentage of basal values, averaged from 4 pre-drug fractions and also as normalized areas under curve (AUC) corresponding to every treatment period. The treatment effects were assessed by one-or two-way repeated measures ANOVA or Student's t-test, as appropriate, using Statistica for Windows software (4.5 version) (StatSoft inc.). Post-hoc analysis was performed using Duncan's test. Data are expressed as means ± SEM. Statistical significance was set at p < 0.05 (two tailed).
Results
Vortioxetine effect on mPFC pyramidal activity. Prevention by the 5-HT 3 -R agonist SR57227A
Vortioxetine (VOR; 0.1e0.2e0.4e0.8e1.6 mg/kg i.v., cumulative doses) dose-dependently increased the firing rate in 10 (77%) of the 13 neurons recorded. Two neurons (15%) were unaffected and another one (8%) decreased its activity. Maximal effect was observed at 0.4 mg/kg i.v. The increased discharge rate persisted for !13 min after the last VOR injection. Fig. 1A shows a representative example of VOR effect on the discharge of an mPFC pyramidal neuron. Fig. 1B and C shows the effect of VOR in all neurons (231 ± 44% of baseline, n ¼ 13) and in activated neurons (273 ± 51% of baseline, n ¼ 10). One-way ANOVA revealed a significant effect of VOR when considering all neurons (F(6,72) ¼ 3.00; p < 0.02, n ¼ 13) or only excited neurons (F(6,54) ¼ 3.21; p < 0.01, n ¼ 10) and posthoc differences between VOR (0.4e0.8e1.6 mg/kg i.v.) and baseline-saline values.
Given the high affinity of VOR for 5-HT 3 -R, we studied the potential prevention of its effect by the 5-HT 3 -R agonist SR57227A by comparing SR57227A þ VOR versus SAL þ VOR. A single dose (1.28 mg/kg i.v.) of SR57227A fully prevented the elevation of pyramidal cell firing induced by VOR. Two-way ANOVA revealed significant effects of pre-treatment (F(1,22) ¼ 4.41; p < 0.05), treatment (F(6,132) ¼ 4.03; p < 0.002) and pre-treatment$treatment interaction (F(6,132) ¼ 2.83; p < 0.02 n ¼ 13 and 11 for SAL þ VOR, and SR57227A þ VOR groups, respectively), with significant post-hoc differences between SAL and SR57227A pretreatments at VOR doses of 0.4, 0.8 and 1.6 mg/kg i.v. Fig. 1D shows a representative example of the lack of an effect of cumulative doses of VOR in SR57227A-pre-treated rats. Fig. 1E shows the prevention by SR57227A of VOR effect in all neurons. The prevention of VOR effect by SR57227A was observed in 10 of the 11 pyramidal neurons. Fig. 1F shows the dose-effect relationships for both experimental groups. Fig. 1 . Effect of vortioxetine (VOR) on the firing rate of layer V (midbrain-projecting) pyramidal neurons in rat medial prefrontal cortex (mPFC) and its prevention by the 5-HT 3 -R agonist SR57227A (SR). A) Representative example of a pyramidal neuron whose discharge was increased by intravenous VOR administration (0.1e0.2e0.4e0.8e1.6 mg/kg i.v., cumulative doses). B) and C) Bar graphs showing the average effect of VOR on firing rate in all neurons (B, n ¼ 13) and in the subpopulation of excited neurons (C, n ¼ 10). D) Representative example of the prevention of VOR effect on mPFC pyramidal discharge by pre-treatment with SR57227A (1.28 mg/kg, i.v.). Note the lack of effect of the 5-HT 3 -R agonist SR57227A on pyramidal discharge. E) Bar graph showing the lack of VOR effect in SR57227A pre-treated rats in all recorded neurons (n ¼ 11). F) Graph showing the comparison between saline (SAL) þ vortioxetine (SAL þ VOR) and SR57227A þ vortioxetine (SR þ VOR) groups. *p < 0.05 versus basal (BAS) and SAL values in SAL þ VOR group; #p < 0.003 SAL versus SR57227A pre-treatments at VOR doses of 0.4, 0.8 and 1.6 mg/kg i.v.
Effect of ESC, OND and ESC þ OND on pyramidal neuron activity in mPFC
The administration of escitalopram (ESC, 0.1e0.2e0.4e0.8e1.6 mg/kg i.v., cumulative doses) did not alter the discharge rate of mPFC pyramidal neurons (n ¼ 9). Five neurons (55.5%) were not significantly activated, 3 were unaffected (33.3%) and 1 was inhibited (11.2%). Fig. 2A and B shows a representative example and the effect of ESC in all recorded neurons, respectively.
Similarly, a single dose of ESC (0.1 mg/kg i.v.) did not affect the firing rate of mPFC pyramidal neurons (n ¼ 8). Five neurons (62.5%) were not significantly inhibited by ESC, 1 (12.5%) was unaffected and 2 (25%) were not significanty activated. Fig. 2C shows the effect of a single dose of ESC in all recorded neurons.
The administration of ondansetron (OND; 0.16e0.32e1.28 mg/ kg i.v., cumulative doses) evoked a dose-dependent increase in pyramidal discharge in 7 out of 11 neurons (63.6%) recorded (4 were unaffected; 36.4%). The maximal effect was achieved at Fig. 2 . Effects of escitalopram (ESC, a selective serotonin reuptake inhibitor, SSRI), ondansetron (OND, a 5-HT 3 -R antagonist) and the combination of escitalopram þ ondansetron (ESC þ OND) on pyramidal neuron activity in mPFC. A) Example of a pyramidal neuron whose discharge was unaffected by ESC cumulative doses administration (0.1e0.2e0.4e0.8e1.6 mg/kg i.v.). B) Bar graph showing the average effect of ESC on firing rate in all neurons (n ¼ 9). C) Graph showing the lack of effect of the administration of a single dose of ESC (0.1 mg/kg i.v., n ¼ 8) during a 25-min period after drug administration. D) Example of a pyramidal neuron whose discharge was augmented by OND cumulative doses administration (0.32e0.64e1.28 mg/kg i.v.). E) and F) Bar graphs showing the average effect of OND on firing rate in all neurons (E, n ¼ 11) and in excited neuron subpopulation (F, n ¼ 7). G) and H) Examples of two pyramidal neurons showing an increase G) or a lack of effect H) after OND administration (1.28 mg/kg i.v., single dose). I) Graph showing the increasing effect on pyramidal activity of single dose of OND in all neurons (n ¼ 9) and in excited neuron subpopulation (n ¼ 6). J) Representative example of a pyramidal neuron response to the administration of the drug combination ESC (0.1 mg/kg i.v.) þ OND (1.28 mg/kg i.v.). K) Graph showing the increasing effect of a single dose of OND on pyramidal activity in all neurons (n ¼ 9) and in excited neuron subpopulation (n ¼ 6). L) Graph showing the comparison between escitalopram (ESC), ondansetron (OND) and escitalopram þ ondansetron (ESC þ OND) groups. *p < 0.05 vs Basal and SAL values in OND (single and cumulative doses) and ESC þ OND groups; #p < 0.05 ESC at 10 0 e15 0 e20 0 e25 0 min after administration versus OND (10e15e20e25 min after administration) and ESC þ OND (5e10e15e20e25 min after administration).
1.28 mg/kg i.v. Fig. 2D shows a representative example of an activated neuron. Fig. 2E and F shows the effect of OND in all neurons (239 ± 55% of baseline, n ¼ 11) and in activated neurons (311 ± 74% of baseline, n ¼ 7). One-way ANOVA revealed a significant effect of OND when considering all neurons (F(4,40) ¼ 2.91; p < 0.05, n ¼ 11) or only excited neurons (F(4,24) ¼ 3.31; p < 0.03, n ¼ 7) with posthoc differences between OND (1.28 mg/kg i.v.) and baseline-saline values. The increased discharge rate persisted for !20 min after the last OND injection. Similarly, a single dose of OND (1.28 mg/kg i.v.) increased the firing rate in 6 of the 9 (66.7%) pyramidal neurons recorded. Two neurons (22.2%) were inhibited and 1 (11.1%) was unaffected. Maximal effect was observed at 10 min postadministration and persisted for the duration of recordings (typically 25 min post-administration). Fig. 2 shows representative examples of activated (2G) and unaffected (2H) neurons. Fig. 2I shows the effect of OND in all neurons (253 ± 73% of baseline, n ¼ 9) and in the subgroup of excited neurons (333 ± 94% of baseline, n ¼ 6). One-way ANOVA indicated a significant effect of the treatment for all neurons (F(6,48) ¼ 2.28; p < 0.03; n ¼ 9) or only excited neurons (F(6,30) ¼ 4.18; p < 0.005; n ¼ 6), with post-hoc differences between OND (1.28 mg/kg i.v. at 10e15e20e25 min after administration) and baseline-saline values.
In order to further clarify the role of 5-HT 3 -R in the enhancing effect on pyramidal activity by VOR, we evaluated the action of ESC þ OND (to mimic the mechanism of action of VOR). This drug combination evoked an increase in the firing rate in 9 out of 12 (75%) recorded neurons. Three neurons (25%) were unaffected. The combination of OND þ ESC increased pyramidal neuron discharge to an extent similar to OND alone. Maximal effect was observed at 10 min post-administration and persisted for the duration of recordings (25 min post-administration). Fig. 2J shows a representative example of an activated neuron. Fig. 2K shows the effect of the drug combination in all neurons (290 ± 52% of baseline, n ¼ 12) and in the subgroup of excited neurons (357 ± 53% of baseline, n ¼ 9). One-way ANOVA indicated a significant effect of treatment considering all neurons (F(6,66) ¼ 5.88; p < 0.0001; n ¼ 12) or only excited neurons (F(6,48) ¼ 7.41; p < 0.00001; n ¼ 9), with post-hoc differences between ESC þ OND at 5e10e15e20e25 min postadministration and baseline-saline values.
Finally, we compared the effects on the mPFC pyramidal discharge induced by the three treatments (ESC, OND, ESC þ OND). Two-way ANOVA (with time and treatment as factors) revealed a significant effect of time (F(6,156) ¼ 7.73; p < 0.00001), treatment (F(2,26) ¼ 3.53; p < 0.05) and treatment Â time interaction (F(12,156) ¼ 1.90; p < 0.05) (n ¼ 8, 9 and 12 for ESC, OND and ESC þ OND groups, respectively), with post-hoc differences between OND or ESC þ OND and ESC (Fig. 2L) .
Effect of systemic administration of ESC and OND on extracellular 5-HT concentration in mPFC and vHPC
OND administration (10 mg/kg s.c.) had no effect alone but augmented the effect of ESC (3.2 mg/kg s.c.) on extracellular 5-HT in mPFC (Fig. 3AeB) and vHPC (Fig. 3CeD) . In mPFC, two-way ANOVA for repeated measures of AUC values revealed significant effects of group (F(3,25) ¼ 11.38; p < 0.00001), treatment (F(2,50) ¼ 17.01; p < 0.00001) and treatment$group interaction (F(6,50) ¼ 8.69; p < 0.00001, n ¼ 4, 6, 10 and 9 for SAL þ SAL, SAL þ OND, ESC þ SAL and ESC þ OND groups, respectively) with significant post-hoc differences between ESC þ OND and ESC. In vHPC, two-way ANOVA for repeated measures of AUC values also revealed significant effects of group (F(3,27) ¼ 10.76; p < 0.0001), treatment (F(2,54) ¼ 11.26; p < 0.0001) and treatment$group interaction (F(6,54) ¼ 9.10; p < 0.00001, n ¼ 5, 5, 9 and 12 for SAL þ SAL, SAL þ OND, ESC þ SAL and ESC þ OND groups, respectively) with significant post-hoc differences between ESC þ OND and ESC.
Relevance of local 5-HT 3 -R in vHPC on vortioxetine effect on extracellular 5-HT: involvement of GABA B -R
To examine the potential involvement of local 5-HT3-R econtaining microcircuits in vHPC in the augmentation of ESC effects by systemic OND, we examined the ability of local OND infusion in vHPC (300 mM in aCSF) to augment the effect of ESC (3.2 mg/kg s.c.) on extracellular 5-HT (Fig. 4A and B) . The s.c. ESC administration increased extracellular 5-HT in vHPC to z3-fold the basal levels. This effect was sustained, lasting for z15 fractions (300 min). The local application of 300 mM OND in vHPC produced a robust potentiation of ESC effect. Two-way ANOVA for repeated measures of AUC values revealed significant effects of group (F(1,12) ¼ 7.75; p < 0.02), treatment (F(2,24) ¼ 42.13; p < 0.00001) and treatment$group interaction (F(2,24) ¼ 9.97; p < 0.001 n ¼ 7 for both ESC and ESC þ OND groups), with significant post-hoc differences between ESC and ESC þ OND. Local OND application alone increased the extracellular 5-HT concentration in vHPC (380 ± 8% of basal values; p < 0.03; n ¼ 5) (Fig. 4C) .
Unlike mPFC, the vHPC lacks afferent pathways to the raphe nuclei that may explain the OND augmentation of ESC effect, thus suggesting the involvement of local microcircuits in this effect. We then hypothesized that 5-HT 3 -R blockade by OND and VOR would reduce GABA release and consequently, the GABA tone on local GABA B -R controlling 5-HT release. We then examined whether the restoration of the GABA B -R tone with baclofen (BAC) could attenuate the augmenting effect of OND on extracellular 5-HT. The local co-perfusion of BAC (100 mM) by reverse dialysis in vHPC fully reversed the increase of extracellular 5-HT produced by the local application of OND after systemic ESC administration, and normalised 5-HT values ( Fig. 4D and E) . One-way ANOVA for repeated measures of AUC values revealed significant effect of treatment (F(3,15) ¼ 10.79; p < 0.0005; n ¼ 6), with significant post-hoc differences between ESC, ESC þ OND and ESC þ OND þ BAC treatments. Moreover, the local perfusion of BAC did not alter ESCinduced increase of extracellular 5-HT (Fig. 4F) . One-way ANOVA for repeated measures of AUC values revealed significant effect of treatment (F(2,10) ¼ 4.77; p < 0.05; n ¼ 6), with no post-hoc differences between ESC and ESC þ BAC treatments.
Similarly, local BAC infusion (100 mM in aCSF) by reverse dialysis in vHPC attenuated the effect of VOR (5 mg/kg s.c.) on extracellular 5-HT. Unlike BAC, local administration of the GABA A -R agonist muscimol (MUS) in vHPC (100 mM in aCSF) failed in reversing VOR effect on extracellular 5-HT ( Fig. 4G and H) . Two-way ANOVA for repeated measures of AUC values revealed significant effects of group (F(2,18) ¼ 9.15; p < 0.002), treatment (F(2,36) ¼ 53.29; p < 0.00001) and the treatment$group interaction (F(4,36) ¼ 14.72; p < 0.00001 n ¼ 9, n ¼ 7 and n ¼ 5 for VOR, VOR þ BAC and VOR þ MUS, respectively) with significant post-hoc differences between VOR or VOR þ MUS and VOR þ BAC treatments.
Discussion
The present results indicate that acute vortioxetine administration dose-dependently increased the discharge rate of mPFC pyramidal neurons projecting to midbrain, with a maximal effect at 0.4 mg/kg i.v. In contrast, escitalopram did not significantly alter the same neuronal population at doses that fully block SERT (vortioxetine: B etry et al., 2013; escitalopram: unpublished observations) . Likewise, vortioxetine increased extracellular 5-HT concentration in mPFC and vHPC to an extent greater than that evoked by escitalopram. This difference is likely due to the simultaneous blockade of SERT and 5-HT 3 -R by vortioxetine, since its effects were prevented by the 5-HT 3 -R agonist SR57227A and were mimicked by escitalopram and ondansetron combinations (and by ondansetron alone for pyramidal discharge elevations).
We suggest that vortioxetine blockade of 5-HT 3 -R disinhibits pyramidal neuron activity and 5-HT release following the removal of the GABAergic tone on pyramidal neurons (mainly mediated by GABA A -R) and on 5-HT nerve terminals (mediated by GABA B -R) (Fig. 5) . Hence, unlike SSRI, vortioxetine increased the glutamatergic/GABAergic neurotransmission ratio in rat brain. These effects may explain the superior effects of vortioxetine in various experimental models, such as neurotransmitter release and pro-cognitive effects in rodents (B etry et al., 2015; Sanchez et al., 2015; Wallace et al., 2014) .
5-HT 3 -Rs are exclusively expressed in GABAergic interneurons in cortical and hippocampal areas (Lee et al., 2010; Morales and Bloom, 1997; Puig et al., 2004) . 5-HT 3 -R have also been identified in GABAergic interstitial cells of the corpus callosum, which may control cortical and subcortical networks (von Engelhardt et al., 2011) . Cortical GABAergic interneurons activate GABA A -R to rapidly control electrical and biochemical signalling in pyramidal neurons. GABAergic interneurons are classified according to their morphology, connectivity, electrophysiological properties and expression profile of neuropeptides and calcium binding proteins, such as parvalbumin (PV), calbindin or calretinin (DeFelipe et al., 2013) . PV-positive neurons are a subpopulation of GABAergic cells comprising chandelier and large basket cells (DeFelipe, 1997) that tightly control neuronal activity via axo-somatic (basket cells) or axo-axonic (chandelier cells) synapses on deep layer pyramidal neurons (DeFelipe and Fariñas, 1992) . In the mPFC, 5-HT 3 -R are expressed in non-PV, non-somatostatin GABAergic interneurons, located in upper cortical layers (Lee et al., 2010; Morales and Bloom, 1997; Puig et al., 2004) , which include neurogliaform cells (Ol ah et al., 2009; Tam as et al., 2003) and VIP-expressing interneurons (Lee et al., 2013; Pi et al., 2013) . The percentage of mPFC GABAergic neurons expressing 5-HT 3 -R is 40% in layer I, 18% in layers II-III, 6% in layer V and 8% in layer VI . Given their predominant location in superficial layers, we expected that 5-HT 3 -R blockade would have a moderate impact on the activity of midbrain-projecting pyramidal neurons, located in layers V-VI (Gabbott et al., 2005) . However, z 70% of the recorded pyramidal neurons showed a marked increase of their discharge rate after 5-HT 3 -R blockade with vortioxetine or ondansetron.
Several reasons may account for this apparent discrepancy. On the one hand, 5-HT 3 -R are ion channels and their physiological stimulation by 5-HT markedly increased the discharge of 5-HT 3 -Rexpressing GABAergic interneurons in mPFC . In agreement, the microiontophoretic and systemic administration of 5-HT 3 -R agonists decreased the firing activity of putative pyramidal neurons in mPFC (Ashby et al., 1991; Bachy et al., 1993; Edwards et al., 1996) . Similar effects have been reported in the hippocampus after the physiological release of 5-HT or local application of 5-HT 3 -R agonists ). Hence, 5-HT 3 -R-expressing interneurons may inhibit pyramidal activity more than anticipated from their location in superficial and middle layers due to the ionic nature of 5-HT 3 -R. On the other hand, 5-HT 3 -R may be present in GABAergic interneurons controlling pyramidal neuron activity via axo-somatic contacts (Freund, 2003; Marlin and Carter, 2014) and/ or in cortical networks of synaptically-and electrically-coupled interneurons (Galarreta and Hestrin, 2001; Tam as et al., 2003; Traub et al., 2001 ). Overall, the present results are consistent with a strong and rapid ionotropic action of 5-HT on a subpopulation of cortical and hippocampal interneurons through the activation of 5-HT 3 -R. The present observations suggest that 5-HT 3 -R are tonically activated by 5-HT in the anesthetized rat since both vortioxetine and ondansetron elevated pyramidal neuron discharge. Given the presence of an excitatory control of the mPFC on 5-HT neuronal activity Hajos et al., 1998) , it is likely that the actions of vortioxetine in mPFC may contribute to the rapid recovery of serotonergic cell firing observed after repeated vortioxetine treatment (B etry et al., 2013; Sanchez et al., 2015) .
The increased pyramidal discharge induced by vortioxetine in mPFC may also be involved in its pro-cognitive effect in rodents (B etry et al., 2015; Sanchez et al., 2015; Wallace et al., 2014) . The PFC is critically involved in cognition, including working memory and executive functions (Miller and Cohen, 2001) . Primate studies have revealed that the neurobiological substrate of working memory is the maintenance of patterns of persistent neuronal activity in the dorsolateral PFC (equivalent to the prelimbic mPFC in rodents) during mnemonic processes (Curtis and D'Esposito, 2003; Fuster and Alexander, 1971) . Hence, the increased pyramidal discharge induced by vortioxetine may facilitate the emergence and maintenance of these activity patterns during working memory tasks.
Another distinctive feature of vortioxetine is its ability to increase extracellular monoamine concentrations above the level produced by SSRI . Here we provide evidence that, at least for 5-HT, this effect is likely due to the removal of a GABA B -R tone on 5-HT terminals following 5-HT 3 -R blockade in local interneurons. Ondansetron augmented the effect of escitalopram on extracellular 5-HT in mPFC and vHPC, indicating that 5-HT 3 -R blockade can facilitate 5-HT release following SERT inhibition in both areas. Further experiments were carried out in vHPC, which -unlike mPFC-lacks direct afferent pathways to midbrain raphe, thus avoiding potential confounding effects due to the distal modulation of serotonergic neuron activity. Local ondansetron Tao et al., 1996) . In control conditions, stimulation of terminal GABA B -R did not affect striatal 5-HT release (Abell an et al., 2000) , possibly due to the existence of a tonic control by endogenous GABA. However, the present results suggest that the removal of the GABA tone on hippocampal GABA B -R disinhibits 5-HT release, and that the restoration of the tone by the prototypical GABA B -R agonist baclofen -but not the GABA A -R agonist muscimolattenuates 5-HT release (see Fig. 4H ).
Conclusions
In summary, the present study indicates that vortioxetine has strong antagonist effects on 5-HT 3 -R which add on top of SERT inhibition to evoke a robust disinhibition of pyramidal neuron activity in mPFC and of 5-HT release in forebrain. Since vortioxetine shows affinity for various 5-HT-R, an additional role of other receptors (e.g., 5-HT 1A -R, 5-HT 1B -R, 5-HT 7 -R) cannot be discarded. However, it is likely that the simultaneous blockade of SERT and 5-HT 3 -R accounts for the differential actions of vortioxetine in rodents, compared to SSRIs, such as the greater increase in extracellular monoamine concentrations and the pro-cognitive actions. The present results also show that, in addition to 5-HT 1A and 5-HT 1B autoreceptors, forebrain serotonergic activity is tonically limited by the activation of 5-HT 3 -R in GABAergic interneurons. The latter inhibitory effect can be exerted at the local level (e.g., by negatively modulating 5-HT release) or distally, via the attenuation of mPFCmidbrain excitatory pathways after the stimulation of 5-HT 3 -R in GABAergic interneurons. The attenuation of these negative feedmechanisms may improve serotonergic activity and therefore, the treatment of major depression. Fig. 5 . Schematic representation of the putative actions of vortioxetine on pyramidal neuron discharge and on 5-HT release. The blockade of 5-HT 3 -R located on GABA interneurons reduces GABA input onto GABA A -R controlling the activity of mPFC pyramidal neurons, thus enhancing their discharge rate. Likewise, blockade of 5-HT 3 -R reduces the GABA tone on terminal GABA B -R controlling 5-HT release by nerve terminals, therefore augmenting the effect of SERT blockade on extracellular 5-HT (see text for an extended discussion).
